Teva Homepage Print this page Site Map
About TevaInvestor RelationsTeva Worldwide

Press Releases

Jerusalem, Israel, July 27, 2010
Teva Reports Strong Second Quarter 2010 Results

Jerusalem, July 23, 2010
Teva Comments on Generic Lovenox® Approval

Jerusalem, Israel, July 16, 2010
Teva Provides Update on Generic Protonix® Litigation

Jerusalem, Israel, July 7, 2010
Teva to Report Second Quarter 2010 Financial Results on July 27, 2010

Jerusalem, July 1, 2010
Teva Introduces First Generic Effexor XR® Capsules in the United States; Awarded 180-Day Period of Marketing Exclusivity

Jerusalem, Israel, June 29, 2010
Teva Announces Approval of Generic Effexor XR®

Jerusalem, June 28, 2010
Teva Announces Launch of Generic ARIMIDEX®

Jerusalem, June 18, 2010
Teva Announces Completion of $2.5 Billion of Senior Notes Offering Secures Financing for ratiopharm Acquisition

Jerusalem, June 15, 2010
Teva Announces Pricing of $2.5 Billion of Senior Notes Secures Financing for ratiopharm Acquisition

Jerusalem, June 4, 2010
Teva Announces Positive Results From a Study Assessing a New Formulation of COPAXONE®

Jerusalem, June 2, 2010
Teva Announces Launch of Generic Differin®

Jerusalem, June 1, 2010
Teva Announces Launch of Generic Yaz® Tablets

Jerusalem, Israel, May 31, 2010
Teva to Present at the UBS Global Specialty Pharmaceuticals Conference

Jerusalem, May 25, 2010
Teva to Present at the 2010 Citi Investment Research Global Health Care Conference

Jerusalem, May 25, 2010
Teva Announces Launch of Generic Valtrex®

Jerusalem, May 19, 2010
Teva Announces Launch and Shipment of Generic Lipitor® Tablets in Canada

Jerusalem, May 18, 2010
Teva Reaches Settlement Agreement With AstraZeneca Regarding Generic Entocort® EC Capsules

Jerusalem, Israel, May 17, 2010
Teva Provides Update on Talampanel for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Jerusalem, May 14, 2010
Teva Announces Tentative Approval of Generic Sensipar®

Jerusalem, May 11, 2010
Teva To Present At The Bank Of America Merrill Lynch Health Care Conference

Jerusalem, May 7, 2010
Teva Provides Update on Las Vegas Trial

Jerusalem, Israel, May 4, 2010
Teva Reports First Quarter 2010 Results

Jerusalem, Israel, May 3, 2010
Teva To Present At The Deutsche Bank 35th Annual Health Care Conference

Jerusalem, April 28, 2010
Teva Announces Launch of Generic Flomax®

Jerusalem, April 23, 2010
Teva Provides Update on Generic Protonix® Litigation

Jerusalem, Israel, April 19, 2010
ADAGIO Analysis Demonstrates that the Natural Progression of Clinical Symptoms in Parkinson's Disease May Be Slower in Earlier Stages

Jerusalem, Israel and Lund, Sweden, April 15, 2010
New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of Multiple Sclerosis

Jerusalem, Israel, April 15, 2010
Teva to Report First Quarter 2010 Financial Results on May 4, 2010

Jerusalem, Israel, April 12, 2010
Teva Announces Copaxone® Reaches One Million Patient Years Of Experience In The Treatment Of Multiple Sclerosis

Jerusalem, April 7, 2010
Teva to Present New Data on Multiple Sclerosis and Parkinson's Disease at the 62nd American Academy of Neurology Annual Meeting

Jerusalem, April 7, 2010
Teva Announces Final Approval of Generic Hyzaar® and Cozaar®

Jerusalem, April 1, 2010
Teva Provides Update on Gemzar® Litigation

Jerusalem, April 1, 2010
Teva Receives Favorable Court Decision Regarding Seasonique®

Jerusalem, April 1, 2010
Teva Settles Generic Eloxatin Litigation

Jerusalem, March 25, 2010
Teva Announces Tentative Approval of Generic Argatroban® Injection

Jerusalem, March 18, 2010
Teva Invites Public to Listen to Webcast of Investor Meeting

Jerusalem, Israel, March 18, 2010
Teva To Acquire ratiopharm

Jerusalem, March 17, 2010
Teva Provides Update on Generic Temodar®

Jerusalem, Israel, March 9, 2010
Teva Announces the Appointment of Dr. Philip Frost As Chairman of Its Board of Directors

Jerusalem, Israel, March 5, 2010
Teva to Present at the Cowen and Company 30th Annual Healthcare Conference

Jerusalem, March 2, 2010
Teva Announces Favorable Court Ruling in Generic Hyzaar® and Cozaar® Litigation

Jerusalem, Israel, February 25, 2010
Copaxone® 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety

Jersulaem, Israel, February 22, 2010
Teva To Present At The 14th Annual Israeli Equities Conference

Jerusalem, Israel, February 16, 2010
Teva Reports Record Full Year 2009 And Fourth Quarter Results

Jerusalem, February 15, 2010
Teva Announces Agreement on Famvir® Patent Challenge

Jerusalem, Israel, February 14, 2010
Eli Hurvitz Takes a Three Week Medical Leave of Absence

Jerusalem, Israel, Lund, Sweden, February 8, 2010
Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regions

Jerusalem, February 5, 2010
Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits

Jerusalem, February 2, 2010
Teva Announces FDA Accepts BLA for XM02

Jerusalem, Israel, January 26, 2010
Teva Receives Favorable Court Decision Regarding Generic Temodar®

Jerusalem, Israel, January 22, 2010
Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab

Jerusalem, Israel, January 21, 2010
Teva Announces Tentative Approval of Generic Femara® Tablets

Jerusalem, Israel, January 19, 2010
Teva to Donate Medicine to Haiti Earthquake Relief Effort

Jerusalem, Israel, January 19, 2010
Teva to Report Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010

Jerusalem, Israel, January 14, 2010
Moody's Upgrades Teva Rating to A3

Jerusalem, Israel, January 8, 2010
Teva To Present At The 28th Annual J.P. Morgan Healthcare Conference

Jerusalem, Israel, January 7, 2010
Teva Presents Strategic Plan to Deliver Strong Growth

Jerusalem, Israel, January 7, 2010
Teva Announces Settlement Agreements With AstraZeneca Regarding Generic Prilosec® and Nexium®

Jerusalem, Israel, January 4, 2010
Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference



Archive:  2010 2009  2008  2007  2006  2005  2004  2003  2002  2001  2000  1999